Latest news

Adalvo is delighted to announce that we have successfully completed dossier filing of Desmopressin 60mcg, 120mcg and 240mcg sub-lingual tablets. With the present submission, we believe we will be amongst...

Aztiq is thrilled to announce the recent establishment of a new entity Arphio a venture initiated in close collaboration with SK Pharma.

Adalvo is delighted to announce that we have successfully completed our Pivotal BE study of Apixaban 5mg Film Coated Tablets.

Adalvo is delighted to announce that our partner, CellResearch Corporation (CRC), a clinical stage company developing innovative stem cell therapies, announced today that the European Commission and the European Medicines...

Adalvo is pleased to announce that we have successfully launched Icatibant in 14 markets. This product is a complex injectable peptide, forming part of our high-value product portfolio offering to...

As this new year begins, Adalvo is delighted to announce that we have successfully completed our Pivotal BE study of Vortioxetine Film-Coated Tablets.

Adalvo is thrilled to announce that we have entered into a strategic collaboration deal with Naari Pharma, a vertically integrated women’s health pharmaceutical business, based in Bangalore, India.

Adalvo is pleased to announce that we have successfully submitted our EU DCP procedure for Nitrofurantoin ER 100mg Capsules, another differentiated product within our portfolio, that was developed based on...

Adalvo, one of the leading B2B global pharmaceutical companies, with commercial partnerships in more than 100 countries, have been certified as one of the Best Places to Work for 2021!...

The Consortium jointly, through Aztiq II HoldCo Limited, will acquire a 100% stake in Alvogen Emerging Markets Holdings Limited, thereby becoming the leading shareholders in Lotus and Adalvo.

We are pleased to announce that our General Manager, Anil Okay has been awarded the Leader of the Year Award 2021, by the Global Generics & Biosimilar Awards committee.

Adalvo is delighted to announce that we successfully completed our Pivotal BE study of Nintedanib 100mg & 150mg soft gel capsules. We are now moving ahead into dossier completion, and...

Adalvo is delighted to announce that we successfully completed our Pivotal BE study of Desmopressin 60mcg, 120mcg and 240mcg sub-lingual tablets. We are now moving ahead into dossier completion and...

We are proud to announce the successful submission of our DCP procedure for our distinguished hybrid / 505(b)(2) asset Gralise®. We expect to launch this high- value asset in H1...

We are extremely delighted to announce that we successfully submitted our DCP procedure for Liraglutide 6mg/ml pre-filled pen on Friday 29th October, which has been developed in close...

Adalvo is delighted to announce that our partner, CellResearch Corporation (CRC), has been awarded an Innovation Passport for CorLiCyte™, by the UK’s regulatory agencies (MHRA, NICE, SMC), becoming one of...

Adalvo is delighted to announce the successful submission of our DCP procedure for Lisdexamfetamine Oral Solution 10mg / ml which has been developed in close collaboration with Laboserve & Pharma-Data....

Adalvo is pleased to announce the successful closure on our DCP procedure for our Icatibant development, a complex injectable peptide product, forming part of our high-value product portfolio offering to...

Adalvo is pleased to announce the successful DCP filing on its Teriflunomide development, a new addition to our high-value product portfolio offering to our partners.

Adalvo is delighted to announce the successful Pivotal BE outcome of its Lisdexamfetamine Oral Solution 10mg / mlwhich has been developed in close collaboration with Laboserve & Pharma-Data.

Adalvo is pleased to announce that we have completed our patient enrollment of our Phase 3 clinical study, to assess the safety and efficacy of Dimethyl Fumarate 30 mg /...